Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo bought 75,417 shares of the stock in a transaction that occurred on Friday, November 25th. The shares were bought at an average cost of GBX 4 ($0.05) per share, with a total value of £3,016.68 ($3,742.31).

Lorenzo Tallarigo also recently made the following trade(s):

  • On Tuesday, October 25th, Lorenzo Tallarigo purchased 77,864 shares of Oxford BioMedica plc stock. The shares were acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £2,335.92 ($2,897.80).
  • On Monday, September 26th, Lorenzo Tallarigo purchased 79,988 shares of Oxford BioMedica plc stock. The shares were acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £2,399.64 ($2,976.85).

Shares of Oxford BioMedica plc (LON:OXB) opened at 3.60 on Wednesday. The stock’s market capitalization is GBX 111.17 billion. The stock has a 50 day moving average price of GBX 3.46 and a 200 day moving average price of GBX 4.15. Oxford BioMedica plc has a 12-month low of GBX 2.98 and a 12-month high of GBX 8.45.

Insider Buying and Selling by Quarter for Oxford BioMedica plc (LON:OXB)

ILLEGAL ACTIVITY WARNING: “Lorenzo Tallarigo Purchases 75,417 Shares of Oxford BioMedica plc (OXB) Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/30/lorenzo-tallarigo-purchases-75417-shares-of-oxford-biomedica-plc-oxb-stock.html.

OXB has been the subject of a number of recent analyst reports. Jefferies Group initiated coverage on Oxford BioMedica plc in a report on Friday, October 21st. They set a “buy” rating and a GBX 8 ($0.10) price target for the company. N+1 Singer reaffirmed a “hold” rating and set a GBX 3.30 ($0.04) price target on shares of Oxford BioMedica plc in a report on Tuesday.

Oxford BioMedica plc Company Profile

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.